NIH Trial Confirms Raxone’s Safety Profile in PPMS, Santhera Reports
News
An exploratory Phase 1/2 clinical trial in primary progressive multiple sclerosis (PPMS) conducted at the National Institutes of Health (NIH) confirms the safety profile of Raxone (idebenone) at a dose ... Read more